ALEMBIC PHARMA

reported a 15 percent on-year (YoY) growth in in consolidated net profit for the June quarter at Rs 154 crore, driven by strong growth in the US generics business that saw a 13 percent increase in sales. The consolidated revenue from operations for the June quarter rose by 10 percent to Rs.1,711 crore. EBITDA for the quarter rose 20% to Rs 288 crore, while the EBITDA margin improved 200 basis points to 17 percent. Sales growth in the US generics market were strong, rising by 13 percent to Rs 523 crore, attributed to new launches and increased market share. The company filed 6 ANDA approvals received during the quarter, 223 Cumulative ANDA approvals. Ex-US International generics grew by 21% to Rs. 328 crore for the quarrtere